Back to results
US 2015/0087642 A1Published application
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
AssigneeSatiogen Pharmaceuticals, Inc.
InventorsBronislava GEDULIN, Andrew A. YOUNG, Howard E. GREENE
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
Claims26
A method for treating an inflammatory intestinal condition comprising non-systemically administering to the distal ileum of an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) and/or an enteroendocrine peptide enhancing agent and/or a nuclear farnesoid X receptor (FXR) agonist.
Dependencies are inferred from the claim text.